The massive $330 million fund from Santé Ventures signals a major shift toward high-complexity MedTech and digital health. With industry deal value reaching a record $97.6 billion entering 2026, capital is increasingly concentrating on “industrial maturity”, prioritizing clinical validation and AI-driven platforms. This week’s tracker explores how strategic acquisitions and targeted Series A rounds are defining this new era.
Medtronic advances its innovation strategy with intent to acquire CathWorks
Medtronic plans to acquire CathWorks, a company aiming to transform how coronary artery disease is diagnosed and treated.
The acquisition is valued at up to $585 million with potential undisclosed earn-out payments post-acquisition. At the date of the acquisition closing, CathWorks will then become a part of Medtronic.
SVP and president of the Coronary & Renal Denervation at Medtronic Jason Weidman
CathWorks President and CEO Ramin Mousavi
Last week’s tracker: Recare, CraniUS and more
Early-stage investor Santé Ventures closes $330M to spread across biotech, MedTech and digital health
Austin, Texas-based Santé Ventures announced its fifth and biggest fund to date, which exceeded the $300 million target its had originally set.
Early-stage companies will remain Santé’s primary target, and especially those looking to tackle areas marked by “clinical complexity, capital inefficiency or outdated care delivery models,” the investor said.
Founding Managing Director and Chief Investment Officer Kevin Lalande
Rein Medical to become part of the Reinsberg Group
The Reinsberg Group unites specialized European companies in the fields of medical technology, hospital infrastructure, imaging systems and the digitalization of healthcare.
Joining the group offers Rein Medical a strong platform for further development. The company benefits from a broader technical know-how and a stable capital base for continuous investment in innovation, research and development.
Rein Medical CEO Philipp Bechtiger
Stratus Medical raises $10M Series B to complete development of new technology
The Series B financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies. It invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform.
The funds will be used to complete development of the Stratus Medical RF Generator and neurovasis basivertebral nerve ablation technology, expand and protect the company’s valuable patent portfolio, and fund a clinical study.
CEO Bret Boudousquie
Gardia closed a €8.5 Million Series A funding to support its AI-powered emergency call system for seniors
The Series A funding was led by Peak, with participation from amberra, butterfly & elephant, existing investors, and several business angels, including BONVENTURE, DvH Ventures, and Beurer.
The funding will accelerate Gardia’s expansion across the DACH region and into international markets, while also deepening its B2B presence in healthcare and care services.
Founders Marlon Besuch and Michael Hummels
SonoVascular raises $6M Series A to support thrombectomy system
Harbright Ventures served as leading investor in the round. Following the deal, Robert Ross, Harbright’s founding partner, joined SonoVascular’s board of directors.
With the funding, the company plans to support the achievement of two milestones in 2026: an FDA approval for a U.S.-based peripheral venous pivotal study, and conduct a first-in-human study for the treatment of pulmonary embolism.
Founder and CEO Daniel Estay
ORamaVR closed $4.5M in late‑seed funding to accelerate its AI‑driven Medical XR Training Platform
The round led by Big Pi Ventures and with additional capital provided by Evercurious VC, both Athens-based technology focused venture capital funds.
The financing will be used to expand the company’s product development and sales efforts, providing XR training software to be used by manufacturers of medical devices and surgical robots.
Co-founder, CEO and CTO George Papagiannakis
Bluedrop Medical picks up $1.2M for diabetic foot ulcer detection tech
The funding comes as part of Enterprise Ireland’s attempt to engage in more late-stage investments. Bluedrop Medical previously brought in nearly $12.4 million in 2023 and said at that time that it had raised nearly $19 million total since its founding in 2015.
The company plans to further its technology, aimed at reducing the rate of preventable amputations for people living with diabetes.
CEO Chris Murphy
